214 related articles for article (PubMed ID: 28356941)
1. Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT.
Ding JH; Yuan LY; Chen GA
Oncol Lett; 2017 Feb; 13(2):647-654. PubMed ID: 28356941
[TBL] [Abstract][Full Text] [Related]
2. Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF.
Ding JH; Yuan LY; Huang RB; Chen GA
Eur J Haematol; 2014 Oct; 93(4):329-39. PubMed ID: 24766194
[TBL] [Abstract][Full Text] [Related]
3. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
[No Abstract] [Full Text] [Related]
4. Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe3O4 magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells.
Zhang W; Qiao L; Wang X; Senthilkumar R; Wang F; Chen B
Int J Nanomedicine; 2015; 10():3275-89. PubMed ID: 25995634
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor effect of combination of annexin A1 knockdown and bortezomib treatment in multiple myeloma in vitro and in vivo.
Jia C; Kong D; Guo Y; Li L; Quan L
Biochem Biophys Res Commun; 2018 Nov; 505(3):720-725. PubMed ID: 30292410
[TBL] [Abstract][Full Text] [Related]
6. STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling.
Wang L; Cao J; Tao J; Liang Y
Expert Opin Drug Saf; 2024 Mar; 23(3):277-286. PubMed ID: 37642368
[TBL] [Abstract][Full Text] [Related]
7. β-catenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib.
Wu C
Oncol Lett; 2022 Jul; 24(1):205. PubMed ID: 35720475
[TBL] [Abstract][Full Text] [Related]
8. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract][Full Text] [Related]
9. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
[TBL] [Abstract][Full Text] [Related]
10. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
[TBL] [Abstract][Full Text] [Related]
11. Gambogenic acid synergistically potentiates bortezomib-induced apoptosis in multiple myeloma.
Chen R; Zhang H; Liu P; Wu X; Chen B
J Cancer; 2017; 8(5):839-851. PubMed ID: 28382147
[No Abstract] [Full Text] [Related]
12. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ
Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356
[TBL] [Abstract][Full Text] [Related]
13. Blockade of deubiquitinase USP7 overcomes bortezomib resistance by suppressing NF-κB signaling pathway in multiple myeloma.
Yao Y; Zhang Y; Shi M; Sun Y; Chen C; Niu M; Zhang Q; Zeng L; Yao R; Li H; Yang J; Li Z; Xu K
J Leukoc Biol; 2018 Dec; 104(6):1105-1115. PubMed ID: 30024656
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells.
Leng Y; Hu X; Li L; Nkwocha J; Satta T; Sharma K; Kmeiciak M; Zhou H; Zhang Z; Zhou L; Chen W; Grant S
Hematol Oncol; 2022 Dec; 40(5):999-1008. PubMed ID: 35789025
[TBL] [Abstract][Full Text] [Related]
15. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic and Apoptotic Effects of Pinostilbene and Bortezomib Combination Treatment on Human Multiple Myeloma Cells.
Staskiewicz A; Wong E; Tucker M; Farhin R; Park J; Saade R; Alkhazali T; Dang T; Wang X
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628771
[TBL] [Abstract][Full Text] [Related]
17. Exosomal mRNAs and lncRNAs involved in multiple myeloma resistance to bortezomib.
Tang JX; Chen Q; Li Q; He YH; Xiao D
Cell Biol Int; 2021 May; 45(5):965-975. PubMed ID: 33372728
[TBL] [Abstract][Full Text] [Related]
18. hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.
Xi H; Li L; Du J; An R; Fan R; Lu J; Wu YX; Wu SX; Hou J; Zhao LM
Oncol Rep; 2017 Feb; 37(2):961-968. PubMed ID: 28000886
[TBL] [Abstract][Full Text] [Related]
19. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
20. [Cdc37 Contributes to bortezomib resistance in multiple myeloma via autophagy].
Liu LT; Deng SH; Zang MR; Zhang JQ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):583-588. PubMed ID: 32810966
[No Abstract] [Full Text] [Related]
[Next] [New Search]
